Neuropreotective effects and mechanism of regulating glutamate transporters in the mice model of Parkinson's disease by 张云龙
封 面 ： 
分类号                    密级                




厦  门   大   学 







工作完成日期     2017年 7月 30日 
  




                             厦门大学 
 






















Neuroprotective Effects and Mechanism of Regulating Glutamate 




博   士   后   姓   名 张云龙 
流动站（一级学科）名称 生物学流动站 






研究工作起始时间     2016 年 7 月 
研究工作期满时间     2017年  7月 
 
 
厦 门 大 学 
























本研究报告属于：  1、保密（ ），  2、不保密（  ） 
纸本在        年解密后适用本授权书； 
电子版在   年解密后适用本授权书。 
   （请在以上相应括号内打“√”） 
 
 
作者签名：      日期：  年 月 日 







































二、人参皂苷 Rb1通过上调谷氨酸转运体在 PD模型小鼠中发挥神经保护效应 
体外实验证实人参皂苷 Rb1 可以保护多巴胺神经元的损伤，但是人参皂苷
Rb1在 PD动物模型上是否会发挥神经保护效应，目前尚未有相关研究。在本部



















































Parkinson's disease (PD) is a common neurodegenerative disease, which is mainly 
appeared in the middle aged and elderly people, and glutamate excitotoxicity 
contributes significantly to the pathogenesis of PD. Glutamate transporter attenuates 
glutamate excitotoxicity via glutamate uptake. Studies have shown that upregulation 
of glutamate transporters could weaken excitotoxic damage to the nervous system, 
protect dopaminergic neuron and ameliorate movement deficiency in PD animal 
models. Therefore, in this study, we focus on the regulatory mechanism of glutamate 
transporters in the pathogenesis of PD and explore the possibility of treating PD by 
promoting glutamate transporter. Our work is divided into two sections as below. 
Part I. Rapamycin upregulates glutamate transporter and IL-6 expression in 
astrocytes in a mouse model of Parkinson’s disease 
Rapamycin protects mice against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)-induced loss of dopaminergic neurons, which is an established model for 
Parkinson’s disease. We demonstrated that rapamycin preserves astrocytic expression 
of glutamate transporters and glutamate re-uptake. The protective effect was also 
observed in astrocyte cultures, indicating that rapamycin acts directly on astrocytes. 
In the MPTP model, rapamycin caused reduced expression of the E3 ubiquitin ligase 
Nedd4-2 and reduced co-localization of glutamate transporters with ubiquitin. 
Rapamycin increased interleukin 6 (IL-6) expression, which was associated with 
reduced expression of inflammatory cytokines, indicating anti-inflammatory 
properties of IL-6 in the MPTP model. NF-κB was shown to be a key mediator for 
rapamycin, while Janus kinase 2, signal transducer and activator of transcription 3, 
phosphoinositide 3-kinase, and Akt partially mediated rapamycin effects in astrocytes. 
These results demonstrate for the first time in a Parkinson’s disease animal model that 

















Part II. Ginsenoside Rb1 confers neuroprotection via promotion of glutamate 
transporters in a mice model of Parkinson’s disease 
Ginsenoside Rb1 has been demonstrated to protect dopaminergic (DA) neurons  
from death in vitro. However, the neuroprotective effects and underlying mechanism 
of Rb1 in treating Parkinson’s disease (PD) remain uncharacterized. In this study, we 
explored the effects of Rb1 on the glutamatergic systems in the 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. Here, for 
the first time, we report that Rb1 treatment ameliorates motor deficits, prevents DA 
neuron death, and suppresses α-synuclein expression and astrogliosis in the MPTP 
mouse model of PD. Rb1 attenuates glutamate excitotoxicity by upregulating 
glutamate transporter expression and function, and modulating the nigrostriatal and 
cortico-nigral glutamatergic transmission pathways. Our results demonstrate that Rb1 
increases glutamate transporter expression via nuclear translocation of nuclear 
factor-kappa B, regulates glutamate receptor expression and promotes synaptic 
protein expression. These results indicate that Rb1 suppresses glutamate 
excitotoxicity and modulate synaptic transmission to improve the impairments in 
motor functions of the MPTP model of PD, suggesting that Rb1 may serve as a 
potential therapeutic agent for PD.   
   In summary, our study focus on glutamate transporters as targets to study the 
mechanisms and neuroprotective effects of rapamycin and Ginsenoside Rb1 in PD 
animal models. We indicate that rapamycin and Ginsenoside Rb1 can reduce 
glutamate excitotoxicity and modulate excitatory synaptic transmission via 
upregulation of glutamate transporters. Thus glutamate transporters are prospective 
drug target in treating Parkinson’s disease.   
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PD患者约 200万，约占世界 PD患者总数的五分之二，预计到 2030年将达到 500
万，我国每年新增 PD患者近 10万人，65岁以上该病的患病率为 1.67% 1。PD
严重危害人类健康，不仅给患者带来巨大的痛苦，也给家庭和社会造成沉重的负







胺含量减少在 70~80%以上 4-6。PD 后期多巴胺能神经元大量死亡，这也是临床
上左旋多巴替代治疗随着 PD疾病的进展疗效逐渐减弱的重要原因。因此，进一
































疗 13,14。但是，NMDA 受体在脑内比 5-羟色胺和多巴胺受体分布更广泛，影响
机体多种生理功能，因而其非选择性拮抗剂的副作用也较为严重 15，并且 NMDA
受体拮抗剂被报道具有成瘾性，可加重 PD患者记忆力的丧失，导致肌张力增加
和震颤等运动障碍，从而导致 PD 病情恶化 15,16。因此，在 PD 发病的早期，针
对兴奋性毒性效应，研发有效的、副作用少的 PD治疗药物越来越受到关注。 




止谷氨酸能传递。兴奋性氨基酸转运体（excitatory amino acid transporters, EAATs，
也称为高亲和力谷氨酸转运体）在清除递质、终止兴奋性突触传递中发挥重要作
用 17,18。真核生物 EAATs分为 GLAST （glutamate/aspartate transporter，也称作
EAAT1）、GLT-1 （glutamate transporter-1，也称作 EAAT2）、EAAC1 （excitatory 





病密切相关 23。早期 Ferraese 等研究发现，与对照组相比，原发性 PD 患者血
小板谷氨酸摄取量减少了 50%，且摄取减少量与 PD 的严重程度有关 24。在 PD





















即 GLT-1 功能的降低不仅是 PD 疾病过程中的一个重要病理因素，很可能也是
PD发病的一个重要始动因素 5。我们前期对 GLT-1在 PD中的表达变化机制及其





























主要分布于神经元突触后膜，参与谷氨酸转运。（引自Benarroch EE. Neurology, 
2010 30） 
1.4 针对 GLT-1靶点的帕金森病治疗药物研究进展 
研究表明，通过上调 GLT-1的表达，可以减轻兴奋性毒性对神经系统的损
伤，保护多巴胺神经元，改善 PD的运动障碍症状。例如，2005年 Rothstein等
筛选了美国 FDA 认证的 1040 种药物，发现包括头孢曲松钠在内的 β-内酰胺类
抗生素可以显著提高 GLT-1的表达。其后的研究表明头孢曲松钠可以通过激活
NF-κB 提高 GLT-1 的表达，降低突触间隙的谷氨酸浓度 31,32。应用头孢曲松钠
治疗 PD 小鼠，发现头孢曲松钠能够在提高 GLT-1 表达的同时，降低 PD 小鼠
黑质和纹状体区多巴胺神经元的死亡，并且头孢曲松钠可以减轻 PD小鼠的运动
行为障碍，改善 PD小鼠的认知能力 33-36。我们的研究也表明头孢曲松钠通过抑
制 NF-κB/JNK/c-Jun 通路提高了 MPP+染毒星形胶质细胞的活力和细胞膜上
GLT-1的表达，并且提高了星形胶质细胞的谷氨酸摄取活性，从而降低了谷氨酸
兴奋性毒性对中枢神经系统的损伤，对多巴胺神经元发挥保护效应 29。国内胡刚
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